Pancreatic Cancer Research

ResearcherShenyang Pharmaceutical UniversityNo recent work listed

Hua Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1903-836X; OpenAlex author ID A5100344257. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 3 papers · 2020: 1 paper · 2021: none · 2022: 2 papers

Papers 10

  1. Ziprasidone suppresses pancreatic adenocarcinoma cell proliferation by targeting GOT1 to trigger glutamine metabolism reprogramming. Co-author DOI 10.1007/s00109-022-02181-8↗
  2. Steroid treatment response combined with serological mark in differentiating type-1 autoimmune pancreatitis from pancreatic cancer. Co-author DOI 10.1097/md.0000000000031660↗
  3. Licocoumarone induces BxPC-3 pancreatic adenocarcinoma cell death by inhibiting DYRK1A. Last author DOI 10.1016/j.cbi.2019.108913↗
  4. Ixocarpalactone A from dietary tomatillo inhibits pancreatic cancer growth by targeting PHGDH. Co-author DOI 10.1039/c9fo00394k↗
  5. Aspulvinone O, a natural inhibitor of GOT1 suppresses pancreatic ductal adenocarcinoma cells growth by interfering glutamine metabolism. Co-author DOI 10.1186/s12964-019-0425-4↗
  6. Prognostic value of pre-treatment peripheral blood markers in pancreatic ductal adenocarcinoma and their association with S100A4 expression in tumor tissue. Co-author DOI 10.3892/ol.2019.10809↗
  7. 8-Chrysoeriol, as a potential BCL-2 inhibitor triggers apoptosis of SW1990 pancreatic cancer cells. Last author DOI 10.1016/j.bioorg.2018.01.042↗
  8. The dietary compound luteolin inhibits pancreatic cancer growth by targeting BCL-2. Last author DOI 10.1039/c8fo00033f↗
  9. A sesquiterpene lactone from Siegesbeckia glabrescens suppresses Hedgehog/Gli-mediated transcription in pancreatic cancer cells. Co-author DOI 10.3892/ol.2016.4994↗
  10. Wnt2 protein plays a role in the progression of pancreatic cancer promoted by pancreatic stellate cells. First author DOI 10.1007/s12032-015-0513-2↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lixia Chen · 5 shared papers, 2018–2022 · strength 0.59
  2. Mengzhu Zheng · 2 shared papers, 2019–2022 · strength 0.27
  3. Zhimei Li · 2 shared papers, 2018 · strength 0.20
  4. Bingqian Liu · 1 shared paper, 2022 · strength 0.17
  5. Bin Zhou · 1 shared paper, 2022 · strength 0.17
  6. Bin Liu · 1 shared paper, 2022 · strength 0.17
  7. Yueying Yang · 1 shared paper, 2022 · strength 0.16
  8. Yong Xu · 2 shared papers, 2015–2019 · strength 0.16
  9. Chao Zhao · 1 shared paper, 2020 · strength 0.13
  10. Yonghui Zhang · 1 shared paper, 2019 · strength 0.11
  11. Weiguang Sun · 1 shared paper, 2019 · strength 0.11
  12. Changxing Qi · 1 shared paper, 2019 · strength 0.11
  13. Shan Yan · 1 shared paper, 2019 · strength 0.11
  14. Yi Pan · 1 shared paper, 2019 · strength 0.11
  15. Zhenguo Song · 1 shared paper, 2019 · strength 0.11
  16. Yiwen Zhang · 1 shared paper, 2018 · strength 0.09
  17. Hwa Jin Lee · 1 shared paper, 2016 · strength 0.07
  18. Jae‐Ha Ryu · 1 shared paper, 2016 · strength 0.07
  19. Chongbiao Huang · 1 shared paper, 2015 · strength 0.05
  20. Huan Zhang · 1 shared paper, 2015 · strength 0.05
  21. Tiansuo Zhao · 1 shared paper, 2015 · strength 0.05
  22. He Ren · 1 shared paper, 2015 · strength 0.05
  23. Jihui Hao · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.